Tubulin-IN-64 是一种靶向微管蛋白 (tubulin) 的磺化苯乙烯基喹唑啉衍生物,具有高选择性抗癌活性,可通过抑制 EGFR/Akt/mTOR 和 EGFR/Ras 信号通路诱导细胞周期阻滞、凋亡 (apoptosis) 和自噬 (autophagy),在斑马鱼胶质母细胞瘤异种移植模型中表现出显著的抗肿瘤作用,可用于胶质母细胞瘤和白血病的研究。
Tubulin-IN-64
产品编号: MS-F61038 分子式: C24H19ClN2O4S 分子量: 466.94
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Tubulin-IN-64 是一种靶向微管蛋白 (tubulin) 的磺化苯乙烯基喹唑啉衍生物,具有高选择性抗癌活性,可通过抑制 EGFR/Akt/mTOR 和 EGFR/Ras 信号通路诱导细胞周期阻滞、凋亡 (apoptosis) 和自噬 (autophagy),在斑马鱼胶质母细胞瘤异种移植模型中表现出显著的抗肿瘤作用,可用于胶质母细胞瘤和白血病的研究。

生物实验数据

生物活性 Tubulin-IN-64 is a sulfonated styrylquinazoline derivative targeting tubulin with highly selective anticancer activity that induces cell cycle arrest, apoptosis, and autophagy by inhibiting the EGFR/Akt/mTOR and EGFR/Ras signaling pathways, exhibits significant antitumor effects in a zebrafish glioblastoma xenograft model, and can be used for research on glioblastoma and leukemia.
IC50 & Target

EGFR

 

Akt

 

Ras

 

mTOR

 

体外研究
(In Vitro)

Tubulin-IN-64 (TS5) (72 h) 人胶质母细胞瘤 U87MG (IC50 = 0.17 μM)、U-251 (IC50 = 0.21 μM) 和人慢性粒细胞白血病 K562 细胞 (IC50 = 0.26 μM) 表现出强效的抗增殖活性,对人肝癌 HepG2 细胞的细胞毒性可忽略不计 (IC50 > 25 μM),对正常人星形胶质细胞 (NHA) 具有中等的抗增殖活性 (IC50 = 1.75 μM),并且对上述癌细胞系的治疗指数 (TI) 分别为 10.3、8.5 和 6.69。
Tubulin-IN-64 (10 μM; 90 min) 体外微管聚合实验中显著促进微管聚合。
Tubulin-IN-64 (0.63 μM; 3 h) 破坏 U-251 细胞中微管的组装-解聚动力学,并诱导微管细胞骨架的紊乱和凝聚。
Tubulin-IN-64 (1.3 μM; 48 h) 诱导 K562 细胞发生明显凋亡,处理后约 50% 的 K562 细胞处于早期和晚期凋亡阶段。
Tubulin-IN-64 (0.4 μM; 24 h) 可诱导 U-251 细胞发生 G2/M 期细胞周期阻滞,下调 EGFR (Tyr1068)、Akt (Ser473)、mTor (Ser2448) 和 STAT5 的磷酸化水平,并上调细胞周期相关蛋白 (p27、p21、cyclin B1、cdc2、Aurora A) 和促凋亡蛋白 (cleaved caspase-9、cleaved PARP-1、BID)。
Tubulin-IN-64 (1.3 μM; 24 h) 可诱导 K562 细胞发生 G2/M 期细胞周期阻滞,下调 EGFR (Tyr1068)、Akt (Ser473)、mTor (Ser2448) 和 STAT5 的磷酸化水平,并上调细胞周期相关蛋白 (p27、p21、cyclin B1、cdc2、Aurora A) 和促凋亡蛋白 (cleaved caspase-9、cleaved PARP-1、BID)。

Cell Autophagy Assay

Cell Line: U-251 cells and K562 cells
Concentration: 0.4 μM and 1.3 μM
Incubation Time: 24 h
Result: Apoptosis was the main mode of cell death in U-251 (no significant autophagy gene changes); in K562, upregulated autophagy-related genes (calreticulin, LC3), indicating autophagy involvement in p53-deficient cell death.

RT-PCR

Cell Line: U-251 cells and K562 cells
Concentration: 0.4 μM and 1.3 μM
Incubation Time: 24 h
Result: Downregulated CCNE2 and IDH1 (U-251) or CCNE2 (K562, 5.8-fold decrease) mRNA expression.
Upregulated GADD45 in both cell lines, and additionally upregulated TUBB3 (> 2.2-fold), calreticulin and LC3 in K562 cells.

Cell Cycle Analysis

Cell Line: U-251 cells and K562 cells
Concentration: 0.4 μM and 1.3 μM
Incubation Time: 24 h
Result: Caused significant G2/M phase cell cycle arrest.

Immunofluorescence

Cell Line: U-251 cells
Concentration: 0.63 μM
Incubation Time: 3 h
Result: Disrupted microtubule polymerization-depolymerization dynamics and induced a disordered microtubule cytoskeletal network.

Western Blot Analysis

Cell Line: U-251 cells and K562 cells
Concentration: 0.4 μM and 1.3 μM
Incubation Time: 24 h
Result: Upregulated the expression of cell cycle-related proteins (p27, p21, cyclin B1, cdc2, Aurora A) and pro-apoptotic proteins (cleaved caspase-9, cleaved PARP-1, BID).
Downregulated the phosphorylation of EGFR (Tyr1068), mTOR (Ser2448) (U-251) or Akt (Ser473), STAT5 (Tyr694) and RAS expression (K562).

Apoptosis Analysis

Cell Line: U-251 cells and K562 cells
Concentration: 0.2/0.4 μM and 1.3 μM
Incubation Time: 48 h
Result: Induced significant apoptosis: nearly 75% of U-251 cells and around 50% of K562 cells underwent early and late apoptosis.
体内研究
(In Vivo)

Tubulin-IN-64 (TS5) (0.5、1、2 μM; 浸泡; 72 h) 在植入 U-251 细胞的斑马鱼胶质母细胞瘤异种移植模型中表现出剂量依赖性的抗肿瘤活性。
Tubulin-IN-64 (1-5 μM; 浸泡; 96 h) 对斑马鱼胚胎具有急性毒性,LC50 值为 3.614 μM,浓度 ≥ 3 μM 时,可诱导斑马鱼幼体出现剂量依赖性的心脏毒性和发育畸形 (脊柱侧弯、心包水肿、腹部混浊)。

Animal Model: Female and male immunocompetent zebrafish embryos (freshly obtained) were used for acute toxicity assay.
Dosage: 1, 2, 3, 4, 5 μM
Administration: Immersion, continuous exposure; 96 h
Result: Exhibited acute toxicity with a median LC50 of 3.614 μM.
Induced developmental endpoints including embryo coagulation, absence of somite formation, tail separation disorder and lack of cardiac activity at concentrations up to 15 μM.
Showed dose-dependent cardiotoxic potential, with noticeable reduction in heart rate (beats per minute) compared to the control group.
Induced developmental malformations including scoliosis (body-axis curvature), pericardial edema and abdominal opacity, with severity and frequency increasing.
Animal Model: Female and male immunocompetent zebrafish embryos (2 days post-fertilization, 2-dpf) were intra-yolk sac injected with human glioblastoma U-251 cells (500-1000 fluorescently labeled cells per embryo.
Dosage: 0.5, 1, 2 μM
Administration: Immersion, continuous exposure; 72 h
Result: Demonstrated dose-dependent antitumor efficacy.
Significantly inhibited tumor growth, quantified by reduced tumor-derived fluorescence at the injection site.
Exhibited sublethal effects without causing severe developmental abnormalities at the tested concentrations.

化学信息

分子量 466.94
分子式 C24H19ClN2O4S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础